Analysis BioNTech’s BNT113 Misses Progression-Free Survival Goal, but AHEAD-MERIT Trial Soldiers On
BioNTech shares closed Friday at EUR 78.05, down 3.0% on the session, capping a bruising stretch for the Mainz-based vaccine and oncology developer. Over the past seven days the stock...